Showing results (241-250 of 296) with videos related to
Sort By:
Pageof 30
JAMA Cardiology|August 30, 2025
Systolic Blood Pressure and Microaxial Flow Pump-Associated Survival in Infarct-Related Cardiogenic Shock: A Post Hoc Analysis of the DanGer Shock Randomized Clinical TrialAstrid Duus Mikkelsen, Rasmus Paulin Beske, Lisette Okkels Jensen, et al.Nature Communications|April 9, 2020
Interference with ERK-dimerization at the nucleocytosolic interface targets pathological ERK1/2 signaling without cardiotoxic side-effectsAngela Tomasovic, Theresa Brand, Constanze Schanbacher, et al.Journal of the American College of Cardiology|June 25, 2025
Effect of Microaxial Flow Pump on Hemodynamics in STEMI-Related Cardiogenic ShockJacob Eifer Møller, Rasmus Paulin Beske, Lisette Okkels Jensen, et al.JAMA Cardiology|October 27, 2024
Microaxial Flow Pump Hemodynamic and Metabolic Effects in Infarct-Related Cardiogenic Shock: A Substudy of the DanGer Shock Randomized Clinical TrialNanna Louise Junker Udesen, Rasmus Paulin Beske, Christian Hassager, et al.Leukemia|March 20, 2025
Three-year analysis of adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3Bijal D Shah, Ryan D Cassaday, Jae H Park, et al.Journal for Immunotherapy of Cancer|August 30, 2023
Impact of prior therapies and subsequent transplantation on outcomes in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3Bijal D Shah, Ryan D Cassaday, Jae H Park, et al.The Lancet. Haematology|May 28, 2021
PET-guided eBEACOPP treatment of advanced-stage Hodgkin lymphoma (HD18): follow-up analysis of an international, open-label, randomised, phase 3 trialStefanie Kreissl, Helen Goergen, Ina Buehnen, et al.American Heart Journal|September 2, 2020
Rationale and design of the MULTISTARS AMI Trial: A randomized comparison of immediate versus staged complete revascularization in patients with ST-segment elevation myocardial infarction and multivessel diseaseBarbara E Stähli, Ferdinando Varbella, Bettina Schwarz, et al.Lancet (London, England)|December 26, 2014
Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin's lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trialKarolin Behringer, Helen Goergen, Felicitas Hitz, et al.Journal of Hematology & Oncology|December 9, 2022
Two-year follow-up of KTE-X19 in patients with relapsed or refractory adult B-cell acute lymphoblastic leukemia in ZUMA-3 and its contextualization with SCHOLAR-3, an external historical control studyBijal D Shah, Armin Ghobadi, Olalekan O Oluwole, et al.Pageof 30